Pradžia › Autoimuninės ligos › Texas › Houston
Autoimuninės ligos klinikiniai tyrimai Houston, TX
Vienas tyrimas dėl Autoimuninės ligos ieško dalyvių vietoje Houston arba jos apylinkėse. Atidarykite jį, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Renkami dalyviai2 fazė
- MD Anderson Cancer Center, Houston
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Renkami dalyviai3 fazė
- Abigail Neiman MD PA, Houston
- Novel Research LLC, Bellaire · už 7 mylių
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Renkami dalyviai2 fazė
- Jade Clinical Site, Houston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Renkami dalyviai1 fazė
- UT MD Anderson Cancer Center, Houston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Renkami dalyviai3 fazė
- Baylor College of Medicine, Houston
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Renkami dalyviai2/3 fazė
- Houston Methodist Hospital - Accepting Adult Patients, Houston
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients, Houston
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Renkami dalyviai2 fazė
- University of Texas - Houston, Houston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Renkami dalyviai3 fazė
- Baylor College of Medicine, Houston
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Renkami dalyviai3 fazė
- GSK Investigational Site, Houston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Renkami dalyviai1/2 fazė
- University of Texas MD Anderson Cancer Center, Houston
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Renkami dalyviai3 fazė
- Nephro Asso North Illinois Indiana, Houston
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Renkami dalyviai1/2 fazė
- Baylor College of Medicine Neurology Department, Houston
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Renkami dalyviai3 fazė
- Texas Children's Hospital/ Baylor College of Medicine, Houston
Study of BHV-1300 in Graves' Disease
Renkami dalyviai1 fazė
- Site-106, Houston
- Site-101, Houston
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Renkami dalyviai3 fazė
- Site Number - 1057, Houston
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Renkami dalyviai2/3 fazė
- Houston Methodist Hospital, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Renkami dalyviaiStebimasis tyrimas
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Renkami dalyviai1/2 fazė
- MD Anderson Texas Medical Center, Houston
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Renkami dalyviaiStebimasis tyrimas
- M D Anderson Cancer Center, Houston
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Renkami dalyviai1/2 fazė
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Renkami dalyviai1 fazė
- Houston Methodist Hospital, Houston
Autoimuninės ligos tyrimai kituose miestuose
- Washington, DC19 tyrimai
- New York City, NY19 tyrimai
- Philadelphia, PA16 tyrimai
- Durham, NC15 tyrimai
- Boston, MA13 tyrimai
- Los Angeles, CA12 tyrimai
- Chicago, IL12 tyrimai
- Dallas, TX9 tyrimai
- Cleveland, OH8 tyrimai
- Milwaukee, WI8 tyrimai
- Atlanta, GA8 tyrimai
- Portland, OR8 tyrimai
Kiti tyrimai Houston
- Nedidelinių ląstelių plaučių vėžys145 tyrimai
- Krūties vėžys126 tyrimai
- Vėžys (visų tipų)121 tyrimas
- Metastatinis vėžys104 tyrimai
- Storosios ir tiesiosios žarnos vėžys102 tyrimai
- Kiaušidžių vėžys89 tyrimai
- Ūmi mieloidinė leukemija85 tyrimai
- Plaučių vėžys78 tyrimai
- Prostatos vėžys76 tyrimai
- Endometrio vėžys68 tyrimai
- Kasos vėžys61 tyrimas
- Melanoma59 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.